CEO of Major U.S. Diagnostics Company Sells $1.5 Million in Shares

On May 11, 2026, Adam H. Schechter, CEO of Labcorp Holdings Inc. (NYSE: LH), sold 5,903 shares of the company’s common stock under a pre-established Rule 10b5-1 trading plan at an average price of $254.50 per share, generating approximately $1.5 million (about KRW 2 billion) in cash.

Following this sale, Schechter still directly holds around 107,000 shares of Labcorp common stock, valued at roughly $27.4 million (about KRW 37 billion) based on recent market prices.

On April 30, 2026, Labcorp reported first-quarter results of $3.54 billion in revenue and $4.25 in adjusted diluted EPS, both surpassing market expectations, and raised its full-year 2026 adjusted EPS guidance.

Recently, Labcorp has expanded partnerships in AI-powered personal health management apps, digital pathology platforms, and precision oncology testing, strengthening its position in digital health and high-value diagnostics.

Headquartered in Burlington, North Carolina, Labcorp is a global diagnostics and medical research company with approximately 70,000 employees. It conducts hundreds of millions of tests annually across about 100 countries, serving hospitals, physicians, pharmaceutical firms, and research institutions.

Before becoming Labcorp’s CEO in 2019, Schechter served as President of Merck’s Global Human Health division. Since joining Labcorp, he has led the spin-off of the Fortrea clinical development business and driven the company’s portfolio realignment.